FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4362543239> ?p ?o ?g. }

• W4362543239 endingPage "5706" @default.
• W4362543239 startingPage "5706" @default.
• W4362543239 abstract "Abstract Tumor-infiltrating lymphocyte (TIL) density has been identified as a prognostic and predictive biomarker in select tumors treated with defined therapies. These observations suggest that TILs may be general markers of patient outcomes, but evidence in support of this hypothesis has been limited by small cohorts. We validated ImmunoPROFILE, a multiplexed immunofluorescence (MIF)-based assay coupled with machine-learning-based image analysis, to identify and quantify tumor cells (cytokeratin, PAX5, PAX8, SOX10), T cells (CD8), T-regulatory cells (FOXP3), exhausted cells (PD-1) and immunosuppressive tumor and immune cells (PD-L1). We applied the MIF panel to specimens from patients collected prospectively over three years and analyzed 2,023 cases across 27 tumor types. The association between biomarkers and overall survival (OS) was investigated using Cox models controlling for patient risk factors such as cancer type, metastatic vs. primary disease, age, and gender. Multivariable biomarker selection was based on likelihood ratios. The assay was highly robust (success rate 97%), reproducible (inter-scanning and intra-staining density controls within 1 SD, inter-staining PD-L1 scores ≤11% CV), and operator-independent (R2 &gt;0.7 to &gt;0.9 for each biomarker and 95% concordance in PD-L1 score-based interpretation between technicians). From whole slide images, a total of 11,932 individual regions of interest were analyzed across the cohort, resulting in &gt;50 million spatially-resolved single cells which were summarized into cell population densities and PD-L1 scores. High densities of CD8+ (&gt;64/mm2, p&lt;0.0001), PD-1+ (&gt;50/mm2, p&lt;0.0001), and FOXP3+ (&gt;30/mm2, p&lt;0.0001) T cells were associated with longer overall survival (OS) irrespective of therapy and across all cancer types. PD-L1 metrics were not associated with OS (p=0.43). Compared to patients with low densities of CD8+ and PD-1+ cells, high densities of at least one of these cell types had better OS (Both high, HR: 0.49, 95% CI: 0.41 - 0.59; CD8+ high, HR: 0.63, (0.48 - 0.82); PD-1+ high, HR: 0.71, (0.54 - 0.93)). The results were consistent in the subset of patients (N=1572) who did not receive immunotherapy (IO). In patients who received IO therapy (N=451), only PD-1+ T-cell density associated with OS (HR: 0.48, (0.36 - 0.65)). To our knowledge, this is the first enterprise-level immune biomarker assay using multiplexed staining, digital imaging, and machine learning to be applied in a prospective manner to clinical specimens at scale. We found that select immune cell densities are prognostic across cancer types and therapies and demonstrated that quantification of multiple cell populations yields better prognostic power than single marker analyses. Citation Format: James Lindsay, Bijaya Sharma, Kristen D. Felt, Anita Giobbie-Hurder, Ian Dryg, Jason L. Weirather, Jennifer Altreuter, Tali Mazor, Priti Kumari, Joao V. Alessi, Ajit J. Nirmal, Michael P. Manos, Ananth R. Kumar, William Lotter, Ethan Cerami, Burce E. Johnson, Neil I. Lindeman, Lynette M. Sholl, Jonathan A. Nowak, Scott J. Rodig. ImmunoPROFILE: A prospective implementation of clinically validated, quantitative immune cell profiling test identifies tumor-infiltrating CD8+ and PD-1+ cell densities as prognostic biomarkers across a 2,023 patient pan-cancer cohort treated with different therapies. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 5706." @default.
• W4362543239 created "2023-04-06" @default.
• W4362543239 creator A5004841883 @default.
• W4362543239 creator A5005519554 @default.
• W4362543239 creator A5011878961 @default.
• W4362543239 creator A5012223543 @default.
• W4362543239 creator A5019874570 @default.
• W4362543239 creator A5028264464 @default.
• W4362543239 creator A5028770636 @default.
• W4362543239 creator A5029288728 @default.
• W4362543239 creator A5039371342 @default.
• W4362543239 creator A5058614093 @default.
• W4362543239 creator A5058975989 @default.
• W4362543239 creator A5064325544 @default.
• W4362543239 creator A5070590609 @default.
• W4362543239 creator A5071787046 @default.
• W4362543239 creator A5071788399 @default.
• W4362543239 creator A5080075412 @default.
• W4362543239 creator A5085305921 @default.
• W4362543239 creator A5085487395 @default.
• W4362543239 creator A5086050132 @default.
• W4362543239 creator A5090956629 @default.
• W4362543239 date "2023-04-04" @default.
• W4362543239 modified "2023-09-26" @default.
• W4362543239 title "Abstract 5706: ImmunoPROFILE: A prospective implementation of clinically validated, quantitative immune cell profiling test identifies tumor-infiltrating CD8+ and PD-1+ cell densities as prognostic biomarkers across a 2,023 patient pan-cancer cohort treated with different therapies" @default.
• W4362543239 doi "https://doi.org/10.1158/1538-7445.am2023-5706" @default.
• W4362543239 hasPublicationYear "2023" @default.
• W4362543239 type Work @default.
• W4362543239 citedByCount "0" @default.
• W4362543239 crossrefType "journal-article" @default.
• W4362543239 hasAuthorship W4362543239A5004841883 @default.
• W4362543239 hasAuthorship W4362543239A5005519554 @default.
• W4362543239 hasAuthorship W4362543239A5011878961 @default.
• W4362543239 hasAuthorship W4362543239A5012223543 @default.
• W4362543239 hasAuthorship W4362543239A5019874570 @default.
• W4362543239 hasAuthorship W4362543239A5028264464 @default.
• W4362543239 hasAuthorship W4362543239A5028770636 @default.
• W4362543239 hasAuthorship W4362543239A5029288728 @default.
• W4362543239 hasAuthorship W4362543239A5039371342 @default.
• W4362543239 hasAuthorship W4362543239A5058614093 @default.
• W4362543239 hasAuthorship W4362543239A5058975989 @default.
• W4362543239 hasAuthorship W4362543239A5064325544 @default.
• W4362543239 hasAuthorship W4362543239A5070590609 @default.
• W4362543239 hasAuthorship W4362543239A5071787046 @default.
• W4362543239 hasAuthorship W4362543239A5071788399 @default.
• W4362543239 hasAuthorship W4362543239A5080075412 @default.
• W4362543239 hasAuthorship W4362543239A5085305921 @default.
• W4362543239 hasAuthorship W4362543239A5085487395 @default.
• W4362543239 hasAuthorship W4362543239A5086050132 @default.
• W4362543239 hasAuthorship W4362543239A5090956629 @default.
• W4362543239 hasConcept C126322002 @default.
• W4362543239 hasConcept C142724271 @default.
• W4362543239 hasConcept C143998085 @default.
• W4362543239 hasConcept C160798450 @default.
• W4362543239 hasConcept C167672396 @default.
• W4362543239 hasConcept C203014093 @default.
• W4362543239 hasConcept C2778326572 @default.
• W4362543239 hasConcept C2779727006 @default.
• W4362543239 hasConcept C2781197716 @default.
• W4362543239 hasConcept C2908647359 @default.
• W4362543239 hasConcept C50382708 @default.
• W4362543239 hasConcept C55493867 @default.
• W4362543239 hasConcept C71924100 @default.
• W4362543239 hasConcept C86803240 @default.
• W4362543239 hasConcept C8891405 @default.
• W4362543239 hasConcept C99454951 @default.
• W4362543239 hasConceptScore W4362543239C126322002 @default.
• W4362543239 hasConceptScore W4362543239C142724271 @default.
• W4362543239 hasConceptScore W4362543239C143998085 @default.
• W4362543239 hasConceptScore W4362543239C160798450 @default.
• W4362543239 hasConceptScore W4362543239C167672396 @default.
• W4362543239 hasConceptScore W4362543239C203014093 @default.
• W4362543239 hasConceptScore W4362543239C2778326572 @default.
• W4362543239 hasConceptScore W4362543239C2779727006 @default.
• W4362543239 hasConceptScore W4362543239C2781197716 @default.
• W4362543239 hasConceptScore W4362543239C2908647359 @default.
• W4362543239 hasConceptScore W4362543239C50382708 @default.
• W4362543239 hasConceptScore W4362543239C55493867 @default.
• W4362543239 hasConceptScore W4362543239C71924100 @default.
• W4362543239 hasConceptScore W4362543239C86803240 @default.
• W4362543239 hasConceptScore W4362543239C8891405 @default.
• W4362543239 hasConceptScore W4362543239C99454951 @default.
• W4362543239 hasIssue "7_Supplement" @default.
• W4362543239 hasLocation W43625432391 @default.
• W4362543239 hasOpenAccess W4362543239 @default.
• W4362543239 hasPrimaryLocation W43625432391 @default.
• W4362543239 hasRelatedWork W2015659076 @default.
• W4362543239 hasRelatedWork W2366649094 @default.
• W4362543239 hasRelatedWork W3006577972 @default.
• W4362543239 hasRelatedWork W3014985680 @default.
• W4362543239 hasRelatedWork W3137070752 @default.
• W4362543239 hasRelatedWork W3194381224 @default.
• W4362543239 hasRelatedWork W3208200361 @default.
• W4362543239 hasRelatedWork W3208891510 @default.
• W4362543239 hasRelatedWork W4248013886 @default.
• W4362543239 hasRelatedWork W4386116984 @default.
• W4362543239 hasVolume "83" @default.
• W4362543239 isParatext "false" @default.

• next